¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"multiple chain"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • heavy-chain disease
    ¹«°Å¿î»ç½½º´, Á߼⺴
  • hemolytic chain
    ¿ëÇ÷»ç½½
  • joining chain
    ¿¬°á»ç½½
  • lateral chain
    °ç»ç½½
  • light chain
    °¡º­¿î»ç½½, °æ¼â
  • light chain disease
    °¡º­¿î»ç½½º´, °æ¼âº´
  • light-chain nephropathy
    °¡º­¿î»ç½½ÄáÆÏº´(Áõ), °æ¼â½ÅÀ庴(Áõ)
  • nuclear chain
    Çٻ罽
  • nuclear chain fiber
    Çٻ罽¼¶À¯, Çٻ罽±Ù(À°)¼¼Æ÷
  • open chain
    ¿­¸°»ç½½
  • open chain form
    ¿­¸°»ç½½Çü
  • open-chain compound
    ¿­¸°»ç½½È­ÇÕ¹°
  • oxidative chain
    »êÈ­¿¬¼â
  • polymerase chain reaction
    ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ
  • respiratory chain
    È£Èí»ç½½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • joining chain
    ¿¬°á»ç½½
  • lateral chain
    (¢¡side chain) °ç»ç½½
  • light chain
    °¡º­¿î»ç½½, °æ¼â
  • nuclear chain
    Çٻ罽
  • open chain
    ¿­¸°»ç½½
  • open-chain compound
    (¢¡open chain) ¿­¸°»ç½½
  • oxidative chain
    »êÈ­¿¬¼â
  • respiratory chain
    È£Èí»ç½½
  • reverberating chain
    ¹ÝÇâ»ç½½
  • side chain
    °ç»ç½½
  • sympathetic chain
    (¢¡sympathetic trunk) ±³°¨½Å°æÁÙ±â
  • gamma chain disease
    °¨¸¶°í¸®º´
  • heavy-chain disease
    Áß°í¸®º´
  • nuclear chain fiber
    Çٻ罽¼¶À¯, Çٻ罽±ÙÀ°¼¼Æ÷
  • open chain form
    ¿­¸°»ç½½Çü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • alpha chain disease
    ¾ËÆÄ¼âº´(¡­áðÜ»).
  • alpha chain disease
    ¾ËÆÄ¼âÁúȯ
  • alpha-chain disease
    ¾ËÆÄ¼â Áúȯ(¡­áð òðü´)
  • gamma-chain disease
    °¨¸¶¼âº´, Gamma-chain º´
  • heavy chain
    Áß¼â
  • heavy chain
    H¼â(¡­áð), Á߻罽.
  • heavy chain
    Áß¼â, Á߻罽, H¼â
  • heavy chain disease
    H¼âº´(¡­áðÜ»), Á߼⺴(ñìáðÜ»).
  • heavy chain disease
    Áß ¼âº´
  • heavy-chain disease
    Á߼⺴
  • hemoglobin a,b-globin chain of
    ¥â-±Û·Îºó¼â(¡­áð)
  • hemolytic chain
    ¿ëÇ÷¿¬¼â.
  • polymerase chain reaction
    ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ
  • polymerase chain reaction
    ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ
  • polymerase chain reaction
    Á¾ÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • chain initiation reaction
    ¿¬¼â°³½Ã¹ÝÀÀ (¡­ËÒã·Úãëë).
  • chain reaction
    ¿¬¼â¹ÝÀÀ(¡­Úãëë).
  • chain saw
    »ç½½ Åé.
  • chain structure
    ¿¬¼â±¸Á¶(ææáðϰðã).
  • chain termination method
    ¿¬¼âÁ¾·á¹ý
  • chain, H
    Áß¼â, Á߻罽, H¼â
  • chain, J
    J¼â, J»ç½½, ¿¬°á»ç½½
  • chain, L
    °æ¼â, °æ»ç½½, L¼â
  • chain, alpha (¥á)
    ¾ËÆÄ»ç½½, ¾ËÆÄ¼â
  • chain, beta (¥â)
    º£Å¸»ç½½, º£Å¸¼â
  • chain, delta (¥ä)
    µ¨Å¸»ç½½, µ¨Å¸¼â
  • chain, eplsilon (¥å)
    ¿¦½Ç·Ð»ç½½, ¿¦½Ç·Ð¼â
  • chain, gamma (¥ã)
    °¨¸¶»ç½½, °¨¸¶¼â
  • chain, heavy
    Áß¼â, Á߻罽, H¼â
  • chain, joining
    ¿¬°á»ç½½, ¿¬°á¼â (=J»ç½½)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • chain
    »ç½½
  • chain conformation
    »ç½½ÀÔüÇüÅÂ(Ø¡ô÷û¡÷¾)
  • chain elongation
    »ç½½¿¬Àå(æÅíþ)
  • chain-growth polymer
    »ç½½½ÅÀå(ãßíþ)ÁßÇÕü(ñìùêô÷)
  • chain initiation
    »ç½½Çü¼º(û¡à÷)°³½Ã(ËÒã·)
  • chain isomer
    »ç½½À̼ºÃ¼(ì¶àõô÷)
  • chain length
    »ç½½ ±æÀÌ
  • chain propagation
    »ç½½ Áõ½Ä(ñòãÖ)
  • chain reaction
    ¿¬¼â¹ÝÀÀ(ææáðÚãëë)
  • chain termination
    »ç½½Çü¼º(û¡à÷) Á¾·á(ðûÖõ)
  • chain termination codon
    »ç½½Çü¼º(û¡à÷) Á¾·á(ðûÖõ) ÄÚµç
  • chain termination mutation
    »ç½½Çü¼º(û¡à÷) Á¾·á(ðûÖõ) º¯ÀÌ(ܨì¶)
  • chain terminator
    »ç½½Çü¼º(û¡à÷) Á¾·áÀÚ(ðûÖõí­)
  • chain terminator method
    »ç½½Çü¼º(û¡à÷) Á¾·áÀÚ¹ý(ðûÖõí­Ûö)
  • closed chain
    "´ÝÈù »ç½½, Æó¼â(øÍáð) (ÔÒ) ring"
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
VL variable domain of the light chain; variable light chain
MCT manual cervical traction; mean cell thickness; mean cell threshold; mean circulation time; mean corp...
MEN Multiple Endocrine Neoplasia
  ; AD Trait
  1. MEN Type I(= Wermer Syndro...
MCS malignant carcinoid syndrome; managed care system; massage of the carotid sinus; mesocaval shunt; me...
AH   1) Atrial Hypertrophy
  2) Anti-Hyaluronidase
  3) Amyloid imm...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HME Hereditary Multiple Exostoses
MAACL Multiple Affect Adjective Check List
MANOVA Multiple Analysis of Variance
MAR Multiple Antibiotic Resistance
MAP Multiple Antigen Peptide
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lambda chain
    ¶÷´Ù »ç½½
  • lateral chain
    Ãø¼â
  • open chain compound
    ¿­¸° »ç½½ È­ÇÕ¹°
  • polymerase chain reaction
    ÁßÇÕ È¿¼Ò ¿¬¼â ¹ÝÀÀ
  • simple-chain peptide

    simplex (´Ü¼ø

  • affecting multiple system
    ´Ù¹ß¼º °èÅëÀ» ħ¹üÇÑ
  • discrete multiple endocrine adenomatosis syndrome
    ºÐ¸®¼º ´Ù¹ß ³»ºÐºñ ¼±Á¾ ÁõÈıº
  • multiple
    ´Ù¹ß¼º, ´Ù¼öÀÇ
  • multiple abutment
    ´Ù¼ö Áö´ëÄ¡
  • multiple allelomorph
    º¹´ë¸³ À¯ÀüÀÚ
  • multiple anchorage
    º¹ÇÕ °íÁ¤
    1Çü½Ä ÀÌ»óÀÇ ÈûÀ» °¡ÇÏ´Â ÀåÄ¡¸¦ »ç¿ëÇÏ´Â °íÁ¤.
  • multiple angioma
    ´Ù¹ß¼º ¸Æ°üÁ¾
  • multiple biologically active peptide fragment
    ´Ù¹ß¼º »ý¹°ÇÐÀû Ȱ¼º ÆéŸÀÌµå ºÐÀý
  • multiple cavernous hemangioma
    ´Ù¹ß¼º ÇØ¸é Ç÷°üÁ¾
  • multiple condylome
    ´Ù¹ß¼º ½À¿ì
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
multiple drug resistant tuberculosis A strain of TB that does not respond to two or more standard anti-TB drugs. MDR-TB usually occurs when treatment is interrupted thus allowing mutations in the organism to occur that confer drug resistance.
(09 Oct 1997)
multiple ego states Various psychological organizational state's reflecting different personas or life experiences.
(05 Mar 2000)
multiple embolism Embolism caused by the arrest of a number of small emboli.
(05 Mar 2000)
multiple endocrine adenomatosis The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance.
Synonym: multiple endocrine adenomatosis.
(05 Mar 2000)
multiple endocrine deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple endocrine neoplasia (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour.
(type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
Origin: Gr. Plassein = to form
(27 Sep 1997)
multiple endocrine neoplasia 1 <radiology> Multiple endrocrine neoplasia syndrome three P's.
Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH
pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression
Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%).
Synonym: Wermer syndrome
(12 Dec 1998)
multiple endocrine neoplasia 2 <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia
Synonym: Sipple syndrome
(12 Dec 1998)
multiple endocrine neoplasia 3 <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B
Synonym: Schimke, marfanoid syndrome
(12 Dec 1998)
multiple endocrine neoplasia type 1 A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients.
(12 Dec 1998)
multiple endocrine neoplasia type 2 <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
(27 Sep 1997)
multiple endocrine neoplasia type 2a A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands.
(12 Dec 1998)
multiple endocrine neoplasia type 2b A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas.
(12 Dec 1998)
multiple epiphysial dysplasia A dominantly inherited abnormality of epiphyses characterised by difficulty in walking, pain and stiffness of joints, stubby fingers, and often dwarfism of short-limb type; on X-ray examination, the epiphyses are mottled and irregular; ossification centres are late in appearance and may be multiple, but the vertebrae are normal. There is also an autosomal recessive form .
Synonym: dysplasia epiphysialis multiplex.
(05 Mar 2000)
multiple exostosis A disturbance of enchondral bone growth in which multiple, generally benign osteochondromas of long bones appear during childhood, commonly with shortening of the radius and fibula; the ill-effects are usually mechanical but malignant change is rare; autosomal dominant inheritance.
Synonym: diaphysial aclasis, hereditary deforming chondrodystrophy, multiple exostosis, osteochondromatosis.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • chain coupling
    »ç½½ ¿¬°á±â
  • chain drive
    (µ¿·ÂÀÇ)üÀÎ Àüµ¿;üÀÎ Àüµ¿À» ÀÌ¿ëÇÑ ÀåÄ¡
  • chain gang
    ÇÑ »ç½½¿¡¸ÅÀÎ ¿Á¿Ü ³ëµ¿ Á˼öµé
  • chain gear
    üÀÎ Åé´Ï¹ÙÄû !
  • chain letter
    ¿¬¼â ÆíÁö;Çà¿îÀÇ ÆíÁö(¹ÞÀº»ç¶÷ÀÌ ´Ù¸¥ ¿©·¯ »ç¶÷¿¡°Ô »çº»À» º¸³¿)
  • chain lightning
    ¿¬¼âÀûÀÎ Áö±×Àç±× ¸ð¾çÀÇ ¹ø°¹ºÒ;½Î±¸·Á(¹ÐÁ¶)À§½ºÅ°
  • chain mail
    »ç½½ °©¿Ê
  • chain measure
    üÀÎ(¾ßµå,ÆÄ¿îµå ¹ý¿¡ ÈñÇÑ Ãø·®¿ë ±æÀÌÀÇ ´ÜÀ§ °è)
  • chain plate
    üÀÎ Ç÷¹ÀÌÆ®(µÀ´ë ¹åÁÙÀ» ¹îÀü¿¡ ¸Å´Âµ¥ ¾²´Â ±Ý¼ÓÆÇ)
  • chain printer
    üÀÎÇÁ¸°ÅÍ(°í¼ÓÀÎÀÚ±âÀÇ ÀÏÁ¾)
  • chain pump
    »ç½½ ÆßÇÁ(»ç½½¿¡ ¹öŶÀ» ´Þ¾Æ ÆÛ¿ï¸®´Â ÀåÄ¡)
  • chain reaction
    ¿¬¼â ¹ÝÀÀ;(»ç°Ç µîÀÇ)¿¬¼â ¹ÝÀÀ
  • chain reactor
    ¿¬¼â ¹ÝÀÀ ÀåÄ¡;¿øÀÚ·Î
  • chain rule
    ¿¬¼â ¹ýÄ¢
  • chain saw
    ÈÞ´ë¿ë µ¿·Â »ç½½Åé;üÀμÒ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á